Search
Lilly's Tirzepatide for Weight Loss Surpasses Late-Stage Trial Goals
2025-08-26 /
Read about 0 minute
Author：小编
Eli Lilly and Co. announced on Tuesday that its daily weight-loss pill, Tirzepatide, has successfully assisted obese patients and those with type 2 diabetes in losing weight during late-stage clinical trials. This achievement not only meets the primary objective of the study but also clears the path for global regulatory approval of the drug.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
